Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Journal of Visualized Experiments : Jove|June 3, 2009
Homemade site directed mutagenesis of whole plasmidsMark Laible, Kajohn Boonrod
Diagnostic Pathology|October 22, 2018
Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissueKerstin Hartmann, Kornelia Schlombs, Mark Laible, et al.
The Journal of Molecular Diagnostics : JMD|April 7, 2018
Transferring a Quantitative Molecular Diagnostic Test to Multiple Real-Time Quantitative PCR PlatformsClaudia Gürtler, Mark Laible, Wolfgang Schwabe, et al.
BMC Cancer|July 17, 2019
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapyMark Laible, Kerstin Hartmann, Claudia Gürtler, et al.
Proteomics|March 21, 2008
Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signalingChristian Löbke, Mark Laible, Claudia Rappl, et al.
Oncotarget|April 28, 2017
TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cellsLeonie Ratz, Mark Laible, Lukasz A Kacprzyk, et al.
BMC Cancer|July 9, 2016
Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimensMark Laible, Kornelia Schlombs, Katharina Kaiser, et al.
Therapeutic Advances in Medical Oncology|March 16, 2026
Evaluating Claudin-6 and isochromosome 12p in the progression from germ cell neoplasia in situ to primary testicular germ cell tumor and post-chemotherapy teratoma: implications for CLDN6-targeted therapiesCiara Conduit, Bruno Valentin Sinn, Catherine Mitchell, et al.
Plos One|April 5, 2013
ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancerLukasz A Kacprzyk, Mark Laible, Tatjana Andrasiuk, et al.
Plos One|September 23, 2021
Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCREmanuele Caselli, Cristina Pelliccia, Valeria Teti, et al.
Pageof 3